Darling Ingredients (NYSE: DAR) reported Q4 EPS of $0.08, $0.10 worse than the analyst estimate of $0.18. Revenue for the quarter came in at $1.15 billion versus the consensus estimate of $841.45 million.

Fourth Quarter 2016 Highlights include:

• Revenue of $1,145 million, an increase of 16% or $158 million
  • 4% organic revenue growth
• Total prescriptions dispensed of 242,000, an increase of 2%
• Gross margin of 7.3% versus 7.8%
  • Gross profit per prescription dispensed of $342, compared to $312
• Net (loss) income attributable to Diplomat of $(1.1) million, compared to $3.6 million
• Adjusted EBITDA of $26.1 million, compared to $28.1 million
  • Adjusted EBITDA margin of 2.3% versus 2.8%
• EPS of $(0.02) per diluted common share versus $0.05
• Adjusted EPS of $0.08 versus $0.21

For earnings history and earnings-related data on Darling Ingredients (DAR) click here.